Schering in Berlin is the first pharmaceutical company to go live with the 5.6 version of Debra, LabLogic Systems' drug metabolism Lims
Debra 5.6 was up and running within four weeks of release, after LabLogic had prepared and performed validation test scripts from Schering's own data and provided users with a three-day training course.
The company collaborated with LabLogic over the splitting and pooling feature that is newly available with 5.6.
This reduces the number of radio-HPLC analyses and therefore the time taken to complete studies, superseding the laborious and error-prone task of cutting and pasting Lims and RC data into Excel.
Another new labour-saver are the extra user-configurable fields and additional comments on each screen of the protocol definition.
Users can record observations and notes within Debra rather than on paper so that all information on a study protocol is recorded directly in the Lims.
The updated document management system can then be used to produce Word protocols and reports, with the facility to compare and track versions of all study documents.
Schering is a research-based pharmaceutical company.
Its activities are focused on four business areas: gynecology and andrology, oncology, diagnostic imaging, and specialised therapeutics for disabling diseases.
As a global player with innovative products, Schering aims for leading positions in specialised markets worldwide.
With in-house excellence in R+D supported by a global network of highly qualified external partners, Schering aims to make a recognised contribution to medical progress and strives to improve the quality of life: 'making medicine work'.
